As a preliminary step toward muscle-mediated gene therapy in the mucopolysaccharidosis (MPS) type VI cat, we have analyzed the transcriptional regulation of feline N-acetylgalactosamine 4-sulfatase (f4S) gene expression from various retroviral constructs in primary cultures of muscle cells. Two retroviral constructs were made containing the f4S cDNA under the transcriptional control of the human polypeptide chain-elongation factor 1alpha (EF1alpha) gene promoter or the cytomegalovirus (CMV) immediate-early promoter. Two further retroviral constructs were made with the murine muscle creatine kinase (mck) enhancer sequence upstream of the internal promoter. Virus made from each construct was used to transduce feline MPS VI myoblasts. The mck ...
Copyright © 2009 Elsevier Inc. All rights reserved.Joint disease in mucopolysaccharidosis type VI (M...
Mucopolysaccharidosis type VI (MPS VI) is a lysosomal storage disease caused by a deficiency of N-ac...
Genetically modified myogenic cells have a number of potentially relevant applications for gene ther...
Fibroblast-mediated ex vivo gene therapy was evaluated in the N-acetylgalactosamine 4-sulfatase (4S)...
AbstractFibroblast-mediated ex vivo gene therapy was evaluated in the N-acetylgalactosamine 4-sulfat...
Mucopolysaccharidosis (MPS) VI is due to a deficiency in the activity of N-acetylgalactosamine 4-sul...
Mucopolysaccharidosis type VI (MPS VI) is an autosomal recessive disease caused by a deficiency of N...
BackgroundMucopolysaccharidosis VI (MPS VI), due to recessively inherited 4-sulfatase (4S) deficienc...
Mucopolysaccharidosis VI (MPS VI) is caused by deficient activity of arylsulfatase B (ARSB), resulti...
Gene therapy may provide a long-term approach to the treatment of mucopolysaccharidoses. As a first ...
In a feline model of mucopolysaccharidosis type VI (MPS VI), recombinant feline N-acetylgalactosamin...
The missense mutation, L476P, in the N-acetylgalactosamine 4-sulfatase (4S) gene, has previously bee...
Autologous transplantation of retrovirally transduced bone marrow (BM) or neonatal blood cells was c...
We report studies that suggest enzyme replacement therapy will result in a significant reduction in ...
We report evidence of a dose responsive effect of enzyme replacement therapy in mucopolysaccharidosi...
Copyright © 2009 Elsevier Inc. All rights reserved.Joint disease in mucopolysaccharidosis type VI (M...
Mucopolysaccharidosis type VI (MPS VI) is a lysosomal storage disease caused by a deficiency of N-ac...
Genetically modified myogenic cells have a number of potentially relevant applications for gene ther...
Fibroblast-mediated ex vivo gene therapy was evaluated in the N-acetylgalactosamine 4-sulfatase (4S)...
AbstractFibroblast-mediated ex vivo gene therapy was evaluated in the N-acetylgalactosamine 4-sulfat...
Mucopolysaccharidosis (MPS) VI is due to a deficiency in the activity of N-acetylgalactosamine 4-sul...
Mucopolysaccharidosis type VI (MPS VI) is an autosomal recessive disease caused by a deficiency of N...
BackgroundMucopolysaccharidosis VI (MPS VI), due to recessively inherited 4-sulfatase (4S) deficienc...
Mucopolysaccharidosis VI (MPS VI) is caused by deficient activity of arylsulfatase B (ARSB), resulti...
Gene therapy may provide a long-term approach to the treatment of mucopolysaccharidoses. As a first ...
In a feline model of mucopolysaccharidosis type VI (MPS VI), recombinant feline N-acetylgalactosamin...
The missense mutation, L476P, in the N-acetylgalactosamine 4-sulfatase (4S) gene, has previously bee...
Autologous transplantation of retrovirally transduced bone marrow (BM) or neonatal blood cells was c...
We report studies that suggest enzyme replacement therapy will result in a significant reduction in ...
We report evidence of a dose responsive effect of enzyme replacement therapy in mucopolysaccharidosi...
Copyright © 2009 Elsevier Inc. All rights reserved.Joint disease in mucopolysaccharidosis type VI (M...
Mucopolysaccharidosis type VI (MPS VI) is a lysosomal storage disease caused by a deficiency of N-ac...
Genetically modified myogenic cells have a number of potentially relevant applications for gene ther...